Download Citation
Article Source:
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Shah MA,
Wainberg ZA,
Catenacci DVT,
Hochster HS,
Ford J,
et al.
(2013)
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLOS ONE 8(3): e54014.
https://doi.org/10.1371/journal.pone.0054014